rozanolixizumab-noli recently approved by the fda under the name of RYTIGGO

Share This Post

rozanolixizumab-noli , a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive was recently approved by the fda under the name of RYTIGGO. (6.26.2023). Congrats to all the members of the researchanddevelopment team who contributed to this achievement!

We at Magellan Biologics & Consulting support the scientific communityworking on R&D projects at #

discovery stage with transient proteinexpression solutions in mammalian cells.

Discover how on: 

Get updates

Subscribe To Our Newsletter

More To Explore

Interested in our products?

Drop us a line and keep in touch

Your cart is currently empty.

Welcome on board!

Subrscribe to our Newsletter
and stay updated!

Get Updates!

If you opt in above we use this information send related content